Related Experiment Video
Updated: Nov 5, 2025
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
Ligand engineering for theranostic applications
Annette Altmann1, Clemens Kratochwil2, Frederik Giesel2
1Department of Nuclear Medicine, University Hospital Heidelberg, Germany; Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Abstract:
Targeted therapy of cancer is considered as promising alternative approach to conventional chemotherapy and radiotherapy. Recent advancements in biotechnology have significantly improved the identification of novel radiopharmaceuticals allowing for more accurate imaging and therapeutic targeting of epithelial tumors. The successful development of radiotracers critically depends on the selection and validation of the tumor-specific target structure, the technical approach employed for the identification of a target-specific ligand, and the evaluation and improvement of the binding properties and the pharmacokinetic profile of the ligand by biotechnological procedures or chemical modification, respectively. Employing rational design of a quinoline-based fibroblast activation protein inhibitor (FAPI) and 'high-through put' display technology using a sunflower trypsin inhibitor1-based peptide library, several FAPI derivatives and a novel αvβ6 integrin-binding peptide (SFITGv6) were identified. FAPI and SFITGv6 represent powerful radiopharmaceuticals for diagnostic imaging and/or endoradiotherapy of FAP- and αvβ6 integrin-expressing epithelial tumors, respectively.
Insights
New radiopharmaceuticals offer improved targeted cancer therapy. Researchers identified fibroblast activation protein inhibitors (FAPI) and alpha-v-beta-6 integrin-binding peptides for precise imaging and treatment of epithelial tumors.
Area of Science:
- Oncology
- Biotechnology
- Radiopharmaceutical Science
Background:
- Targeted cancer therapy presents a promising alternative to traditional chemotherapy and radiotherapy.
- Advancements in biotechnology enhance the development of novel radiopharmaceuticals for precise imaging and therapy of epithelial tumors.
Purpose of the Study:
- To identify and validate novel radiopharmaceuticals for targeted cancer therapy.
- To develop fibroblast activation protein inhibitors (FAPI) and alpha-v-beta-6 integrin-binding peptides for diagnostic imaging and endoradiotherapy.
Main Methods:
- Rational design of quinoline-based fibroblast activation protein inhibitors (FAPI).
- High-throughput screening of a sunflower trypsin inhibitor 1-based peptide library.
- Identification of a novel alpha-v-beta-6 integrin-binding peptide (SFITGv6).
Main Results:
- Several FAPI derivatives were identified.
- A novel alpha-v-beta-6 integrin-binding peptide, SFITGv6, was discovered.
- FAPI and SFITGv6 show potential as radiopharmaceuticals.
Conclusions:
- FAPI and SFITGv6 are effective radiopharmaceuticals for targeting FAP- and alpha-v-beta-6 integrin-expressing epithelial tumors, respectively.
- These agents hold promise for improved diagnostic imaging and endoradiotherapy in oncology.
More Related Videos
Related Concept Videos
02:40Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
00:49Ligand Binding and Linkage